Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.

摘要: Abstract Chimeric immune receptors (CIRs) are functionally pleiotropic because they artificially expressed on diverse cell types, which gives specificity to their function anergize, kill, or protect cognate target cells. CIRs consist of chimeric antigen (CARs) and B-cell antibody receptor (BAR) autoantibody (CAARs). Approval CAR-T therapy by the Food Drug Administration (FDA) has encouraged investigators search for autoimmune therapies that CIR-based. Both T effector cells, particularly CD8+, CD4+ regulatory cells (Tregs) can be engineered through CIR expression. Recently, natural killer have been included increase efficiency. Unwanted producer B effectively prevented CAAR-T (BAR)-T BAR-Treg, represents an advantage in antibody-mediated diseases such as pemphigus vulgaris (PV) hemophilia A. Although CAAR BAR-T may curative benefits autoantibody-mediated diseases, verification long-term efficacy safety a priority before clinical use. Effective CIR-T largely depends reliability stability receptor. Based functionality, factors explicitly determine effectiveness treatment should considered. These include antigen/autoantibody specificity, single chain variable fragment (scFv) affinity, masking. Herein, we review current evidence with focus therapeutic potential challenges.